BIO KEY INTERNATIONAL INC (NASDAQ: BKYI), a biometric identity software company, carries roughly 1.37 million shares in pending overhang — warrants, convertible note balances, and other instruments that could become freely tradeable stock. That figure equals 102.5% of the company's estimated 1.33 million-share tradeable float, earning BKYI a dilution risk grade of 8 out of 10 (HIGH).
The centerpiece is a single block: 1,236,668 warrants — contracts giving the holder the right to buy shares at a fixed price — struck at $4.06 and held entirely by Armistice Capital Master Fund. The company is contractually required to hold a stockholder meeting within 120 days of August 10, 2026, to obtain the Nasdaq-mandated approval for exercise. If shareholders do not approve, management must keep calling meetings every 90 days until they do. A resale registration — the SEC filing that would let the shares be freely sold on the open market — is targeted to become effective within 90 days. Both clocks are running.
Full exercise would take shares outstanding from 1,436,344 to approximately 2,673,012. That is an 86% increase.
The Repricing Ratchet
This is not a one-time event. Armistice has been BKYI's sole warrant inducement counterparty across four consecutive cycles, each one retiring an out-of-the-money position and replacing it with fresh, lower-struck paper at one-to-two times the prior coverage. The strike has fallen from $31.50 to $18.50 to $21.50 to $10.20 to the current $4.06 — a 92% cumulative decline. The warrant count, meanwhile, has grown from 103,056 to 1,236,668. The overhang has never retired. It has compounded.
A 4.99% beneficial ownership cap — a contractual ceiling on the percentage of outstanding shares one holder may own at any moment — means Armistice must distribute shares into the market as it exercises. Exercised shares are structurally sold, not warehoused.
The Note Layer
Beneath the warrant overhang sits a roughly $325,000 residual balance on a senior secured promissory note held by Streeterville Capital, a Salt Lake City firm run by John M. Fife. The note has no stated conversion price. Instead, principal is serially "partitioned" into new promissory notes that are then exchanged for common stock at negotiated near-market prices — functioning as a floorless variable-rate convertible. Two such exchanges occurred in the fourteen days before the most recent quarterly filing: $200,000 converted into 43,308 shares at approximately $4.62, then $150,000 into 37,792 shares at roughly $3.97. The effective price stepped down 14% between tranches.
A Float Larger Than Screeners Show
Data services currently report BKYI's float at approximately 963,000 shares. That figure has not absorbed 618,334 shares issued on the full exercise of the prior Armistice warrant tranche on August 11, nor 81,100 shares issued to Streeterville in the two note exchanges. XBRL filings confirm shares outstanding grew 32.3% in the eight weeks ending August 11. The reconstructed float is roughly 1.33 million — 38% higher than screener feeds indicate.
BKYI has 170 million shares authorized against 1.44 million outstanding, leaving ample room for future issuance. The company has executed five reverse splits since 2015, compounding to approximately one-for-34,560, a pattern consistent with repeated dilution followed by share-count consolidation. The most recent, a one-for-ten, took effect April 30, 2026, following a Nasdaq minimum-bid deficiency.
The Streeterville note matures March 30, 2027, and the lender holds a monthly redemption right of up to $135,000 with an automatic 1% balance escalation if the company falls short — a mechanism that forces continued exchange activity regardless of market conditions.